Načítá se...
The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the < 29 wGA group and a...
Uloženo v:
| Vydáno v: | Ital J Pediatr |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5557508/ https://ncbi.nlm.nih.gov/pubmed/28807039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13052-017-0390-8 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|